Kazia Therapeutics

AU: KZA

AU$21m market cap

AU$0.43 last close

Kazia Therapeutics has two clinical stage anti-cancer drugs: GDC-0084 (targeting glioblastoma) and Cantrixil (targeting ovarian cancer). GDC-0084 was inlicensed from Genentech, and Kazia is seeking other in-licence opportunities.

Investment summary

Kazia Therapeutics is developing two groups of anti-cancer compounds, including GDC-0084, a PI3K inhibitor licensed from Genentech that has been granted orphan designation in the US for glioblastoma. It began recruitment in a US-based Phase II programme for GDC-0084 in Q118; an initial Phase IIa dose-optimisation study will precede a randomised Phase IIb trial in 224 first-line glioblastoma patients (final data due 2021). It will also investigate GDC-0084 in breast cancer brain metastases (in collaboration with Dana Farber) and in the childhood brain cancer DIPG (with St Jude Hospital). The Phase I trial of its third-generation benzopyran drug Cantrixil in ovarian cancer has identified the MTD and is recruiting a 12-patient expansion cohort to further explore safety and potential efficacy. While the primary aim of the dose escalation phase was to assess safety and tolerability, we note that 3/5 patients achieved stable disease after two cycles, one of whom went on to achieve a partial response when treated with Cantrixil in combination with chemo.

Y/E Jun
Revenue (A$m)
EBITDA (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2017A 8.6 (10.2) (10.9) (22.81) N/A N/A
2018A 13.0 (4.9) (6.3) (12.48) N/A N/A
2019E 3.9 (13.3) (14.7) (29.71) N/A N/A
2020E 14.0 (7.2) (8.5) (16.96) N/A N/A
Last updated on 19/09/2018
Industry outlook

Kazia Therapeutics is a biotechnology company listed on the ASX and NASDAQ. Its two main drug technology platforms are third-generation benzopyrans and a PI3K inhibitor.

Last updated on 19/09/2018
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (A$m) 0.8
Forecast gearing ratio (%) N/A
Key management
Iain Ross Chairman
James Garner CEO